Survodutide

GLP-1R agonism reduces appetite through hypothalamic signaling, slows gastric emptying, and stimulates glucose-dependent insulin secretion, producing the weight loss and glycemic benefits shared with semaglutide and tirzepatide. GCGR agonism adds hepatic effects: activation of glucagon signaling in hepatocytes increases fatty acid oxidation, reduces de novo lipogenesis, and mobilizes hepatic triglycerides. Together these effects produce weight loss comparable to GLP-1 monotherapy with superior hepatic fat reduction, relevant for MASH treatment.

Glucagon receptor activation increases basal metabolic rate through brown adipose tissue thermogenesis and hepatic glycogenolysis. In the context of combined GLP-1R/GCGR agonism, the GCGR-driven energy expenditure increase is not offset by hypoglycemia (as pure glucagon injection would cause) because GLP-1R-stimulated insulin secretion maintains glucose balance. This metabolic compensation is the key rationale for dual agonism over pure GLP-1R or GCGR agonism.

In Phase 2 obesity trials (n=387 non-diabetic adults), survodutide 4.8 mg weekly achieved mean weight reduction of approximately 19% at 46 weeks, with ~15-16% achieved by the 2.4 mg dose. Compared to placebo (~2% reduction), all doses showed superior efficacy. GI adverse events (nausea, vomiting, diarrhea) were dose-dependent and consistent with the GLP-1 class, without additional safety signals from the GCGR component.

Phase 2 MASH trials showed significant reductions in liver fat content (MRI-PDFF), ALT, and liver stiffness with survodutide versus placebo, with resolution of MASH without worsening fibrosis in a higher proportion of patients compared to GLP-1 monotherapy benchmarks from historical data. The GCGR-driven hepatic fat mobilization is proposed as the mechanism for improved MASH outcomes beyond weight loss alone.